Price
No data yet.
Social Signal Score
Revenue
$685.8K+149.55%Company Profile
- CEO
- John Perlowski
- Sector
- Financial Services
- Industry
- Asset Management - Bonds
- Beta
- 0.98
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 1.06
Financials
BHV has only 7 quarterly periods on file — the charts below show the full history available.
Revenue
$685.8K+149.5%Net Income
$1.40MEBITDA
$1.60MFree Cash Flow
$218.1K-46.6%EPS (diluted)
$0.88Shares Outstanding (diluted)
1.59M-1.5%Operating Expenses
$0.00Cash & Debt
$1.57MReturn of Capital
$402.7KDividend per Share
$0.05Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.00M | $-1.49M | $-0.94 |
| 2024 | $917.2K | $690.5K | $0.43 |
| 2023 | $-70.5K | $-811.6K | $-0.51 |
| 2022 | $1.13M | $-3.36M | $-2.09 |
| 2021 | $1.43M | $1.44M | $0.90 |
| 2020 | $1.18M | $457.6K | $0.28 |
Valuation
BHVhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70-41.67%Social Signal Score
Mentions (3)
- Newsprnewswire.com·8d ago·Negative
Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026 Oral presentation selected: Phase 1 findings from the ongoing BHV1530-101 study will be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), a leading international forum for early-phase oncology drug development. First-in-class FGFR3 ADC: …
View source ↗ - Newsseekingalpha.com·39d ago·Neutral
…Biohaven Ltd. maintains a Buy rating, driven by pivotal trial progress in protein degraders and a key licensing deal for its Kv7 platform with SK Biopharmaceuticals. BHVN-1300's phase 3 for Graves' disease is underway; BHV-1400's phase 3 for IgA nephropathy is set to start in H2 2026. Opakalim [BHV-7000] for refractory focal epilepsy is fully enrolled in phase 2/3, with topline data expected in H2 2026 and a $350M upfront SK Biopharmaceuticals deal secured.
View source ↗ - Newsprnewswire.com·56d ago·Positive
Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results First extracellular protein degraders in the clinic demonstrate rapid and robust pharmacodynamic effects and compelling safety in nearly 200 individuals dosed, Phase 3 trial underway Positive clinical biomarker and patient data presented from Biohaven's extracellular degrader platform demonstrated deep, rapid, selective lowering of disease-driving antibodies with BHV-1300 in Graves' disease and BHV-1400 IgA N
View source ↗
Insider trading
Open-market buys and sells by BHV officers and directors.
- Bought
- $11.7m
- Sold
- $17.3m
4 trades
7 trades
- Lynch Catherine A.bought
- Lynch Catherine A.bought
- Citigroup Incsold
- Citigroup Incsold
- Cavanagh Richardbought
- Citigroup Incbought
- Blackrock Funding Incsold
- Blackrock Funding Incsold
55 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in BHV.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.